Diabetic retinopathy (DR), with increasing incidence, is the major cause of vision loss and
blindness worldwide in working-age adults. Diabetic macular edema (DME) remains the …

Diabetic macular edema (DME) is the major cause of vision loss in diabetic persons.
Alteration of the blood–retinal barrier is the hallmark of this disease, characterized by …

Background The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and
ranibizumab in the treatment of diabetic macular edema are unknown. Methods At 89 …

Background: Diabetic retinopathy is a leading cause of visual impairment in working-age
adults worldwide. Duration of diabetes is a major risk factor associated with the development …

Purpose To compare efficacy and safety of 2 dosing regimens of intravitreal aflibercept
injection (IAI) with macular laser photocoagulation for diabetic macular edema (DME) …

Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes
mellitus, representing a major cause of visual impairment in developed countries …

Diabetic macular edema (DME) is the most common cause of vision loss in patients with
diabetic retinopathy with an increasing prevalence tied to the global epidemic in type 2 …

Diabetes mellitus (DM) is a important health problem that induces ernestful complications
and it causes significant morbidity owing to specific microvascular complications such as …

Background Diabetic macular oedema (DMO) is a common complication of diabetic
retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk …

Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and
ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic …